Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension.

Sun Pharmaceutical Advanced Research Co. Ltd. has divulged new macrocyclic ATM kinase inhibitors potentially useful for the treatment of cancer.

Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis.

Merck Sharp & Dohme LLC (MSD) has synthesized new protein zer-1 homolog (Hzyg, ZER1) ligands potentially useful for the treatment of cancer.

Yaoya Technology (Shanghai) Co. Ltd. has discovered new pyrimidothiopyrandione GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.

Blueprint Medicines Corp. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized new Kelch-like ECH-associated protein 1 (KEAP1) activators and nuclear factor erythroid 2-related factor 2 (NRF2) degradation inducers potentially useful for the treatment of cancer.

Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported new CDK4/cyclin D1 inhibitors potentially useful for the treatment of breast cancer.

Beijing Earthwise Technology Co. Ltd. has patented new molecular glue degraders comprising an E3 ubiquitin-protein ligase-binding moiety acting as E3 ligase/proto-oncogene Vav (VAV1) interaction inducers and VAV1 degradation inducers.

Boyuan Pharmaceutical (Suzhou) Co. Ltd. has divulged new pyridone derivatives potentially useful for the treatment of HIV infection.